Normal-Tissue Tolerance to Radiopharmaceutical Therapies, the Knowns and the Unknowns

Authors: Richard L. Wahl, George Sgouros, Amir Iravani, Heather A. Jacene, Daniel A. Pryma, Babak Saboury, Jacek Capala, Stephen A. Graves - Journal of Nuclear Medicine 2021 cited by 89

Radiopharmaceutical therapies are gaining increasing prominence as they improve survival in patients with common diseases such as metastatic prostate cancer ([ 1 ][1],[ 2 ][2]). However, whereas sodium iodide (131I) therapy has been used for over 70 y in treating malignant and benign thyroid